Related Experiment Video
Updated: Feb 18, 2026

A Rapid, Scalable Method for the Isolation, Functional Study, and Analysis of Cell-derived Extracellular Matrix
Published on: January 4, 2017
Biomarkers of the extracellular matrix and of collagen fragments
Georgios K Chalikias1, Dimitrios N Tziakas1
1University Cardiology Department, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Insights
Cardiac extracellular matrix (ECM) changes are common in heart diseases. Circulating collagen peptides may serve as useful biomarkers for diagnosing and predicting heart failure (HF).
Area of Science:
- Cardiology
- Biochemistry
- Biomarker Discovery
Background:
- Extracellular matrix (ECM) alterations are hallmarks of major cardiac diseases, including ischemic, pressure overload, and volume overload heart diseases, as well as cardiomyopathies.
- Collagen types I and III are key myocardial structural proteins, and their circulating pro- or telopeptides can indicate collagen synthesis and degradation.
Purpose of the Study:
- To review and summarize published data on cardiac ECM and its circulating biomarkers.
- To analyze studies focusing on collagen metabolism biomarkers in heart failure (HF) patients.
- To discuss limitations in the clinical application of these biomarkers.
Main Methods:
- Literature review of studies on cardiac ECM and collagen metabolism biomarkers.
- Analysis of clinical trial data concerning diagnostic and prognostic utility in heart failure.
- Discussion of current limitations for clinical use.
Main Results:
- Circulating collagen peptides show potential as non-invasive indicators of ECM remodeling in cardiovascular diseases.
- These biomarkers may reflect disease activity and progression in heart failure patients.
- Clinical trials are exploring their diagnostic and prognostic value.
Conclusions:
- Cardiac ECM remodeling is a significant factor in heart disease.
- Circulating collagen peptides offer a promising avenue for biomarker development in cardiology.
- Further research is needed to overcome limitations for widespread clinical adoption.
Abstract:
A great body of evidence has shown that extracellular matrix (ECM) alterations are present in the major types of cardiac diseases: ischemic heart disease, heart disease associated with pressure overload, heart disease associated with volume overload, and intrinsic myocardial disease or cardiomyopathy. Collagen, type I and III, is the principal structural protein found in the myocardium and its pro- or telopeptides are released into the circulation during the course of cardiovascular diseases. Therefore, these peptides may reflect collagen synthesis and break-down and also represent a much more useful tool to address ECM changes from a distance. Clinical trials have been performed during recent years to examine the usage of these peptides as diagnostic or prognostic biomarkers in heart failure (HF) patients. This review aims to summarize published data concerning cardiac ECM and its circulating biomarkers. Studies that focused on collagen metabolism related biomarkers in patients with HF are analyzed. Finally, limitations associated with the clinical use of the aforementioned biomarkers are also discussed.
More Related Videos
Related Concept Videos
The Extracellular Matrix
The Extracellular Matrix
In order to maintain tissue organization, many animal cells are surrounded by structural molecules that make up the extracellular matrix (ECM). Together, the molecules in the ECM maintain the structural integrity of tissue as well as the remarkable specific properties of certain tissues.
Composition of the Extracellular Matrix
The extracellular matrix (ECM) is commonly composed of ground substance, a gel-like fluid, fibrous components, and many structurally and functionally diverse...
Extracellular Matrix
Role of Matrix Metalloproteases in Degradation of ECM
Collagens are the Major Structural Proteins of ECM
Connective tissue proper includes loose...
Overview of Cell-Matrix Interactions

